11 unchanged sentences
On July 29, 2019, we completed the initial public offering of our common stock (our “IPO”), pursuant to which we issued and sold 4,600,000 shares of our common stock, including 600,000 shares associated with the full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $16.00 per share.
−Removed: The offer and sale of all of the shares of our common stock in the IPO were registered under the Securities Act pursuant to our Registration Statements on Form S-1, as amended (File Nos.
+Added: The offer and sale of all of the shares of our common stock in the IPO were registered under the Securities Act of 1933, as amended (the “Securities Act”) pursuant to our Registration Statements on Form S-1, as amended (File Nos.
333-232369 and 333-232796), which were declared or became effective on July 24, 2019.
−Removed: There has been no material change in our planned use of the net proceeds from the IPO as described in the final prospectus filed with the SEC on July 26, 2019 relating to our Registration Statements on Form S-1 (File Nos.
+Added: There has been no material change in our planned use of the net proceeds from the IPO as described in the final prospectus filed with the Securities and Exchange Commission (the “SEC”) on July 26, 2019 relating to our Registration Statements on Form S-1 (File Nos.
333-232369 and 333-232796).
2 unchanged sentences
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
+Added: Stock Performance Graph
+Added: The following information is not deemed to be "soliciting material" or to be "filed" with the SEC or subject to Regulation 14A or 14C under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or to the liabilities of Section 18 of the Exchange Act, and will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent we specifically incorporate it by reference into such a filing.
+Added: The graph below compares the cumulative total stockholder return of our common stock to the Nasdaq Composite Index and the Nasdaq Biotechnology Total Return Index.
+Added: The graph and table below assume that $100 was invested on December 31, 2019, and dividends, if any, were reinvested on the date of payment without payment of any commissions.
+Added: The comparisons in the table are required by the SEC and are not intended to forecast or be indicative of future performance of our common stock.
+Added: 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
+Added: Castle Biosciences, Inc.
+Added: $ 100.00 $ 195.37 $ 124.73 $ 68.49 $ 62.79 $ 77.54
+Added: Nasdaq Composite Index $ 100.00 $ 143.64 $ 174.36 $ 116.65 $ 167.30 $ 215.22
+Added: Nasdaq Biotechnology Total Return Index $ 100.00 $ 125.46 $ 125.49 $ 112.78 $ 117.96 $ 117.30
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.